- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 270457, 5 pages
Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study
1IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRCCS IRST), Via P. Maroncelli 40,47014 Meldola, Italy
2Department of Urology, Morgagni Pierantoni Hospital, Via C. Forlanini 34, 47121 Forli, Italy
Received 19 October 2012; Revised 8 January 2013; Accepted 9 January 2013
Academic Editor: Tavan Janvilisri
Copyright © 2013 Valentina Casadio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. A. Strope and G. L. Andriole, “Prostate cancer screening: current status and future perspectives,” Nature Reviews Urology, vol. 7, no. 9, pp. 487–493, 2010.
- F. H. Schröder, J. Hugosson, M. J. Roobol et al., “Prostate-cancer mortality at 11 years of follow-up,” New England Journal of Medicine, vol. 366, no. 11, pp. 981–990, 2012.
- F. H. Schröder, J. Hugosson, T. L. J. Tammela et al., “ERSPC Screening and prostate-cancer mortality in a randomized European study,” New England Journal of Medicine, vol. 360, no. 13, pp. 1320–1328, 2009.
- E. A. M. Heijnsdijk, A. Der Kinderen, E. M. Wever, G. Draisma, M. J. Roobol, and H. J. De Koning, “Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer,” British Journal of Cancer, vol. 101, no. 11, pp. 1833–1838, 2009.
- O. W. Brawley, D. P. Ankerst, and I. M. Thompson, “Screening for prostate cancer,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 264–273, 2009.
- J. Groskopf, S. M. J. Aubin, I. L. Deras et al., “APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer,” Clinical Chemistry, vol. 52, no. 6, pp. 1089–1095, 2006.
- T. Wu, E. Giovannucci, J. Welge, P. Mallick, W. Y. Tang, and S. M. Ho, “Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis,” British Journal of Cancer, vol. 105, no. 1, pp. 65–73, 2011.
- H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, “Cell-free nucleic acids as biomarkers in cancer patients,” Nature Reviews Cancer, vol. 11, no. 6, pp. 426–437, 2011.
- K. Jung, M. Fleischhacker, and A. Rabien, “Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1611–1624, 2010.
- R. Mead, M. Duku, P. Bhandari, and I. A. Cree, “Circulating tumour markers can define patients with normal colons, benign polyps, and cancers,” British Journal of Cancer, vol. 105, no. 2, pp. 239–245, 2011.
- P. Ulivi, L. Mercatali, W. Zoli et al., “Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection,” Thorax, vol. 63, no. 9, pp. 843–844, 2008.
- J. Ellinger, D. C. Müller, S. C. Müller et al., “Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies,” Urologic Oncology, vol. 30, no. 4, pp. 509–515, 2012.
- E. Gordian, K. Ramachandran, I. M. Reis, M. Manoharan, M. S. Soloway, and R. Singal, “Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 8, pp. 1984–1991, 2010.
- H. Schwarzenbach, C. Alix-Panabières, I. Müller, N. Letang, J.-P. Vendrell, and X. Rebillard, “Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer,” Clinical Cancer Research, vol. 15, no. 3, pp. 1032–1038, 2009.
- V. Casadio, D. Calistri, M. Tebaldi et al., “Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data,” Urologic Oncology, 2012.
- M. Zancan, F. Galdi, F. Di Tonno et al., “Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis,” International Journal of Biological Markers, vol. 24, no. 3, pp. 147–155, 2009.
- T. Szarvas, I. Kovalszky, K. Bedi et al., “Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment,” Oncology Reports, vol. 18, no. 2, pp. 405–409, 2007.
- S. Jahr, H. Hentze, S. Englisch et al., “DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells,” Cancer Research, vol. 61, no. 4, pp. 1659–1665, 2001.
- A. S. Ishkanian, C. A. Mallof, J. Ho et al., “High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer,” Prostate, vol. 69, no. 10, pp. 1091–1100, 2009.
- J. D. Oxley, M. H. Winkler, D. A. Gillatt, and D. S. Peat, “Her-2/neu oncogene amplification in clinically localised prostate cancer,” Journal of Clinical Pathology, vol. 55, no. 2, pp. 118–120, 2002.
- Y. Tabach, I. K. Sakin, Y. Buganim et al., “Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer,” PLoS ONE, vol. 6, no. 1, Article ID e14632, 2011.
- S. A. Bustin, V. Benes, J. A. Garson et al., “The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments,” Clinical Chemistry, vol. 55, no. 4, pp. 611–622, 2009.
- P. M. Bossuyt, J. B. Reitsma, D. E. Bruns et al., “Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative,” Clinical Chemistry, vol. 49, no. 1, pp. 1–6, 2003.
- A. Altimari, A. D. Grigioni, E. Benedettini et al., “Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer,” American Journal of Clinical Pathology, vol. 129, no. 5, pp. 756–762, 2008.
- J. Ellinger, P. J. Bastian, K. I. Haan et al., “Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators,” International Journal of Cancer, vol. 122, no. 1, pp. 138–143, 2008.
- Y. H. Su, M. Wang, D. E. Brenner et al., “Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be used in the detection of colorectal cancer,” Journal of Molecular Diagnostics, vol. 6, no. 2, pp. 101–107, 2004.
- M. Yeager, N. Chatterjee, J. Ciampa et al., “Identification of a new prostate cancer susceptibility locus on chromosome 8q24,” Nature Genetics, vol. 41, no. 10, pp. 1055–1057, 2009.
- J. Sun, W. Liu, T. S. Adams et al., “DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies,” Prostate, vol. 67, no. 7, pp. 692–700, 2007.
- W. Liu, C. C. Xie, Y. Zhu et al., “Homozygous deletions and recurrent amplications implicate new genes involved in prostate cancer,” Neoplasia, vol. 10, no. 8, pp. 897–907, 2008.
- M. van Duin, R. van Marion, K. Vissers et al., “High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer,” Genes Chromosomes and Cancer, vol. 44, no. 4, pp. 438–449, 2005.